Board of Directors
Acarix’s board of directors is the highest decision-making body after the general meeting of shareholders.
Werner Braun
Chairman of the Board and board member since 2016.
Background
Dr. Werner Braun has long-term international experience from leading positions in MedTech companies in Germany, Austria, Switzerland and the United States. Dr. Braun has a PhD in physics from the Technical University of Munich, Germany. He is currently Chairman of the Board and assigned CEO of Miracor Medical Systems GmbH and the CEO of WEMANITEC GmbH. In the past five years, Dr. Braun has been the CEO of BIOTRONIK SE & Co. and an external board member of Technologies Ltd. Chilworth.
Acarix holdings
Shares: 3,600
Warrants: 20,000
Claus Andersson
Board member since 2010.
Background
Dr. Claus Andersson is a partner in the venture capital company Sunstone Capital. He has been a member of the board in 17 companies, serving as Chairman in six of them. Present assignments include, amongst others, Cantargia AB and FBC Device ApS. Dr. Andersson has 12 years of experience in venture capital, an industrial background in blood diagnostics founding four companies in Europe since the year 2000, and has maintained a strong collaboration with the University of Copenhagen, Denmark. Dr. Andersson has an MSc in chemistry and a PhD in mathematical statistics from the University of Copenhagen and Humboldt University in Berlin.
Acarix holdings
Shares: 0
Warrants: 0
Paolo Raffaelli
Board member since 2019.
Background
Paolo Raffaelli has over 20 years of management experience in commercial international positions in both sales and marketing. Paolo’s latest assignment was Marketing and Education Director EMEA at Abbott for the Cardiac Rhythm Management business. Previously Paolo worked as Global Marketing VP for Maquet Critical Care, and before that he was over 12 years with Medtronic, covering several business and marketing management roles in the CRM and Interventional Cardiology business areas, including the general manager role for Medtronic Sweden. Paolo holds an MBA from IMD Business School in Lausanne, Switzerland and lives with his family in Stockholm, Sweden.
Acarix holdings
Shares: 0
Warrants: 0
Hong Yun Fei
Board member since 2016.
Background
Hong Yun Fei holds an MSc in pharmaceutical science. He is currently the CSO of Chinese listed company ZheJiangJingxin Pharmaceutical Co. LTD., with long experience from the company in R&D, strategy and investment. Mr. Yun Fei is also a board member of ShangHai RuiTai Bio-technology CO. Furthermore, he has experience of being director of three other companies and a consultant for two Chinese venture capital companies. Mr. Yun Fei has a close relationship with Fudan University and ZheJiang University, China.
Acarix holdings
Shares: 0
Warrants: 0
Johanne Louise Brændgaard
Board member since 2018.
Background
Johanne Louise Brændgaard has long experience of global sales, marketing and product management from the MedTech industry from positions in Cook Medical and Getinge. Before entering the MedTech industry, she worked in venture capital and IT. Brændgaard has an MSc in international business economics from Aalborg University in Denmark.
Acarix holdings
Shares: 0
Warrants: 0
Ulf Rosén
Partner. Board member since 2014.
Background
Ulf Rosén is General Partner at the investment company SEED Capital, responsible for investments in medical technology and digital health solutions. Since the late 1990s, he has been Chairman of the Board, board member and CEO in several Scandinavian companies in the medical technology, pharma and service sectors. Mr. Rosén’s earlier assignments include CEO of NeoPharma AB (trade sale), CEO Attana AB (asset transfer), Chairman of the Board in Trial Form Support International (partial exit to PE), member of the board in Observe Medical AB (trade sale), General Manager of Fresenius-Kabi AB, Deputy CEO of the Global Nutrition Division of Fresenius-Kabi, CEO of Pharmacia & Upjohn AS and CEO of Globen Ögonklinik AB. He is one of three owners of SEED Capital Management.
Acarix holdings
Shares: 0
Warrants: 0